IMMUNOHISTOCHEMICAL STUDY OF CD44 AND OCT3/4 EXPRESSION IN COLORECTAL CANCER SAMPLES OF IRAQI PATIENTS.

Experimental oncology Pub Date : 2025-07-11 DOI:10.15407/exp-oncology.2025.01.044

Noah A MahmoodМахмуд, Firas S Salah, Zaynab S Abdulghany, Khansaa R Al-Saadi, Hayder A Hassoon, Tiba H Jaafar, Rasha A Hussein

{"title":"IMMUNOHISTOCHEMICAL STUDY OF CD44 AND OCT3/4 EXPRESSION IN COLORECTAL CANCER SAMPLES OF IRAQI PATIENTS.","authors":"Noah A MahmoodМахмуд, Firas S Salah, Zaynab S Abdulghany, Khansaa R Al-Saadi, Hayder A Hassoon, Tiba H Jaafar, Rasha A Hussein","doi":"10.15407/exp-oncology.2025.01.044","DOIUrl":null,"url":null,"abstract":"Background: Colorectal cancer (CRC) is one of the most common cancer types diagnosed globally with high rates of morbidity and mortality. Several biomarkers are associated with cancer stem cells present in various solid tumors, including CRC.Aim: This study aimed to investigate the expression of CD44 and OCT3/4 cancer stem cell markers in samples of CRC biopsies and benign colon tumors of Iraqi patients using the immunohistochemical (IHC) technique.Materials and methods: The IHC analysis was used to determine CD44 and OCT3/4 expression levels in tissue samples of 42 CRC cases and 18 benign neoplasms.Results: The findings revealed a significant increase in high expression levels of CD44 in CRC cases (81%) vs 23% in benign tumor tissue samples. Similarly, a significant rise in OCT3/4 expression was observed in CRC cases (66%) compared to benign tumors (29%). The expression levels of CD44 and OCT3/4 were significantly associated with the CRC stages.Conclusion: Our data indicated that CD44 and OCT3/4 may play a role in CRC progression.","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"47 1","pages":"44-50"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15407/exp-oncology.2025.01.044","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Colorectal cancer (CRC) is one of the most common cancer types diagnosed globally with high rates of morbidity and mortality. Several biomarkers are associated with cancer stem cells present in various solid tumors, including CRC.

Aim: This study aimed to investigate the expression of CD44 and OCT3/4 cancer stem cell markers in samples of CRC biopsies and benign colon tumors of Iraqi patients using the immunohistochemical (IHC) technique.

Materials and methods: The IHC analysis was used to determine CD44 and OCT3/4 expression levels in tissue samples of 42 CRC cases and 18 benign neoplasms.

Results: The findings revealed a significant increase in high expression levels of CD44 in CRC cases (81%) vs 23% in benign tumor tissue samples. Similarly, a significant rise in OCT3/4 expression was observed in CRC cases (66%) compared to benign tumors (29%). The expression levels of CD44 and OCT3/4 were significantly associated with the CRC stages.

Conclusion: Our data indicated that CD44 and OCT3/4 may play a role in CRC progression.

查看原文本刊更多论文

伊拉克结直肠癌患者cd44和oct3/4表达的免疫组化研究

背景：结直肠癌（CRC）是全球最常见的癌症类型之一，发病率和死亡率都很高。几种生物标志物与各种实体肿瘤（包括结直肠癌）中存在的癌症干细胞相关。目的：应用免疫组化（IHC）技术，探讨CD44和OCT3/4肿瘤干细胞标志物在伊拉克结直肠癌活检和良性结肠肿瘤组织中的表达。材料与方法：采用免疫组化法检测42例结直肠癌和18例良性肿瘤组织样本中CD44和OCT3/4的表达水平。结果：研究结果显示，CRC病例中CD44的高表达水平显著增加（81%），而良性肿瘤组织样本中CD44的高表达水平为23%。同样，与良性肿瘤（29%）相比，CRC病例中OCT3/4表达显著升高（66%）。CD44和OCT3/4的表达水平与CRC分期有显著相关性。结论：我们的数据表明CD44和OCT3/4可能在结直肠癌的进展中起作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental oncology

自引率

0.00%

发文量